Efficacy of Controlled-Release Paroxetine in the Treatment of Late-Life Depression

帕罗西汀 安慰剂 临床终点 萧条(经济学) 内科学 重性抑郁障碍 晚年抑郁症 医学 随机对照试验 心理学 精神科 抗抑郁药 海马结构 经济 病理 替代医学 宏观经济学 扁桃形结构 海马体
作者
Mark Hyman Rapaport,Lon S. Schneider,David L. Dunner,J. Davies,Cornelius D. Pitts
出处
期刊:The Journal of Clinical Psychiatry [Physicians Postgraduate Press, Inc.]
卷期号:64 (9): 1065-1074 被引量:97
标识
DOI:10.4088/jcp.v64n0912
摘要

Depression is the second most common neuropsychiatric disorder in older Americans, with significant clinical and public health costs. Despite advances in treatment, late-life depression remains a clinical challenge. Although the selective serotonin reuptake inhibitors (SSRIs) are the most common pharmacologic intervention for late-life depression, few placebo-controlled trials have assessed the efficacy of SSRIs for this condition.In this 12-week, multicenter, placebo-controlled, flexible-dose, double-blind, randomized trial, 319 elderly patients (mean age = 70 years) were treated with controlled-release paroxetine (paroxetine CR) up to 50 mg/day (N = 104), immediate-release paroxetine (paroxetine IR) up to 40 mg/day (N = 106), or placebo (N = 109). Patients met DSM-IV criteria for major depressive disorder and had a total score of 18 or more on the 17-item Hamilton Rating Scale for Depression (HAM-D). The primary efficacy measure was change from baseline to endpoint in HAM-D total score.The primary efficacy analysis showed an adjusted difference between change from baseline in HAM-D score for paroxetine CR and placebo of -2.6 (95% confidence interval [CI] = -4.47 to -0.73, p = .007) at the week 12 last-observation-carried-forward (LOCF) endpoint. The adjusted difference between paroxetine IR and placebo was -2.8 (95% CI = -4.65 to -0.99, p = .003) at week 12. Paroxetine CR and IR were more effective than placebo, with mean +/- SD endpoint HAM-D total scores of 10.0 +/- 7.41 and 10.0 +/- 7.10, respectively, for the active treatments compared with 12.6 +/- 7.34 for placebo. Response, defined as a score of 1 or 2 on the Clinical Global Impressions-global improvement scale, was achieved by 72% of paroxetine CR patients (LOCF; p < .002 vs. placebo), 65% of paroxetine IR patients (p = .06 vs. placebo), and 52% of placebo patients. Remission, defined as a HAM-D total score < or = 7, was achieved by 43% of paroxetine CR patients (LOCF; p = .009 vs. placebo), 44% of paroxetine IR patients (p = .01 vs. placebo), and 26% of placebo patients. In a post hoc analysis, mean HAM-D improvement for paroxetine CR and paroxetine IR was greater than for placebo in both chronically depressed patients (duration > 2 years) and those with short-term (< or = 2 years) depression. Dropout rates due to adverse events were 12.5% for paroxetine CR, 16.0% for paroxetine IR, and 8.3% for placebo.Paroxetine CR and paroxetine IR are effective and well tolerated treatments for major depressive disorder in elderly patients, including those with chronic depression.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
FashionBoy的应助被胡萝卜卜采纳,获得10
刚刚
刚刚
刚刚
搜集达人的应助被liugm采纳,获得10
1秒前
Hiccup完成签到,获得积分10
1秒前
bbf完成签到,获得积分10
1秒前
1秒前
慕青的应助被梦寐寤寐采纳,获得10
2秒前
老师一怒之下给我十篇nuture完成签到,获得积分10
2秒前
1111发布了新的文献求助10
2秒前
00hello00发布了新的文献求助10
2秒前
初七完成签到 ,获得积分10
3秒前
3秒前
枫丶发布了新的文献求助10
4秒前
李健的应助被Kin采纳,获得10
4秒前
科研通AI2S的应助被bfs采纳,获得10
4秒前
bm023061完成签到,获得积分20
4秒前
Broxiga完成签到,获得积分10
4秒前
小马甲的应助被积极鱼采纳,获得10
5秒前
6秒前
6秒前
子衿发布了新的文献求助30
7秒前
当康康发布了新的文献求助10
8秒前
Hello的应助被123采纳,获得10
8秒前
自律的王一博完成签到,获得积分10
8秒前
Dream完成签到 ,获得积分10
9秒前
魁梧的马里奥完成签到,获得积分10
9秒前
sinalpha10发布了新的文献求助10
10秒前
他山之鱼发布了新的文献求助30
10秒前
海盗船长发布了新的文献求助10
10秒前
10秒前
10秒前
10秒前
爱笑麦丽素完成签到 ,获得积分10
11秒前
11秒前
12秒前
ww完成签到 ,获得积分10
12秒前
Jasper的应助被辣个男人采纳,获得10
12秒前
13秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193425
求助须知:如何正确求助?哪些是违规求助? 9579620
关于积分的说明 21866505
捐赠科研通 7793025
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484128